Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • News

JCR and Acumen Partner to Develop Alzheimer’s Therapy Using J-Brain Cargo®

  • The Pharma Data
  • July 16, 2025

JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical…

Read MoreJCR and Acumen Partner to Develop Alzheimer’s Therapy Using J-Brain Cargo®
  • Business

PCI Pharma Services Enters New Growth Phase with Strategic Investment

  • The Pharma Data
  • July 16, 2025

PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO)…

Read MorePCI Pharma Services Enters New Growth Phase with Strategic Investment
  • Regulatory

FDA Grants De Novo Nod to Reflow’s Spur Stent System

  • The Pharma Data
  • July 15, 2025

Reflow Medical Receives FDA De Novo Clearance for Spur Stent System, Marking a Breakthrough in Treatment of Below-the-Knee Peripheral Arterial Disease Reflow Medical, Inc., a pioneering company in the development…

Read MoreFDA Grants De Novo Nod to Reflow’s Spur Stent System
  • Business

CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines

  • The Pharma Data
  • July 15, 2025

CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully…

Read MoreCEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines
  • Regulatory

Samsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe

  • The Pharma Data
  • July 15, 2025

Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in…

Read MoreSamsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe
  • News

New Guideline Expands Access to Advanced Liver Ultrasound, Experts Say

  • The Pharma Data
  • July 15, 2025

New Guidelines Expand Access to Advanced Liver Imaging and Transplant Evaluations Using Contrast-Enhanced Ultrasound A new policy change is being hailed by medical experts as a transformative advancement in the…

Read MoreNew Guideline Expands Access to Advanced Liver Ultrasound, Experts Say
  • Press Releases

HistoSonics Secures Coverage for Liver Tumor Therapy in 7M Highmark Members

  • The Pharma Data
  • July 15, 2025

HistoSonics Expands Access to Groundbreaking Non-Invasive Liver Tumor Treatment as Highmark Covers Histotripsy for 7 Million Members In a pivotal development for patients battling liver tumors, HistoSonics, the medical technology…

Read MoreHistoSonics Secures Coverage for Liver Tumor Therapy in 7M Highmark Members
  • Research

Acadia Unveils New Team and Pipeline, Eyes Biotech Powerhouse Status

  • The Pharma Data
  • July 15, 2025

Acadia Pharmaceuticals Unveils Ambitious Growth Strategy, Eyes $12 Billion Pipeline with Female-Led R&D Powerhouse More than three decades after its founding in 1993, Acadia Pharmaceuticals is embracing a bold new…

Read MoreAcadia Unveils New Team and Pipeline, Eyes Biotech Powerhouse Status
  • Research

Takeda Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1

  • The Pharma Data
  • July 15, 2025

Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development…

Read MoreTakeda Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1
  • Press Releases

ViiV Expands MPP Deal for Long-Acting HIV Treatment Access

  • The Pharma Data
  • July 15, 2025

ViiV Healthcare Broadens Voluntary Licensing Deal with MPP to Include Long-Acting Injectable HIV Treatment in Global Access Push GSK plc (LSE/NYSE: GSK) announced that its majority-owned subsidiary, ViiV Healthcare—a global…

Read MoreViiV Expands MPP Deal for Long-Acting HIV Treatment Access
  • News

Baxdrostat Meets All Endpoints in Phase III Hypertension Trial

  • The Pharma Data
  • July 15, 2025

Baxdrostat Achieves Positive Results in Phase III BaxHTN Trial, Demonstrating Significant Blood Pressure Reduction in Patients with Uncontrolled or Resistant Hypertension AstraZeneca has announced promising top-line results from its pivotal…

Read MoreBaxdrostat Meets All Endpoints in Phase III Hypertension Trial
  • News

WHO Sets Up Collaborative Networks for Pathogen Genomics Surveillance

  • The Pharma Data
  • July 12, 2025

WHO’s International Pathogen Surveillance Network Launches Communities of Practice to Advance Genomic Surveillance The World Health Organization’s (WHO) Hub for Pandemic and Epidemic Intelligence has taken a major step forward…

Read MoreWHO Sets Up Collaborative Networks for Pathogen Genomics Surveillance
PrevNext
UK Biotech Day
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Synthetic Design Lab Debuts First Logic-Gated ADC at AACR 2026, Delivering ≥10X Enhanced Targeted Cancer Cell Killing
  • Lundbeck Showcases Real-World Improvements in Migraine-Related Cognitive Symptoms with VYEPTI® at AAN 2026
  • Zai Lab Highlights Preclinical Data Showing ZL-1503 Delivers Rapid Itch Relief and Anti-Inflammatory Effects in Atopic Diseases
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.